Antifosfolipidantistoffer og antifosfolipidsyndrom

Translated title of the contribution: Antiphospholipid antibodies and antiphospholipid syndrome

Rasmus Søgaard Hansen*, Julie Brogaard Larsen, Pernille Vinholt, Anne Voss, Anders Abildgaard

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review


Individuals with antiphospholipid syndrome (APS) have antibodies directed against phospholipid-binding proteins (aPL). The condition is most associated with an increased risk of thromboembolism and obstetric complications. The 2023 classification criteria for APS include six clinical domains (venous thromboembolism, arterial thrombosis, microvascular events, obstetric events, cardiac valve, thrombocytopaenia) and two laboratory domains (lupus anticoagulant, and anti-cardiolipin or anti–β2-glycoprotein-I antibodies). Diagnosis and treatment of APS are specialist tasks and are summarised in this review.
Translated title of the contributionAntiphospholipid antibodies and antiphospholipid syndrome
Original languageDanish
Article numberV11230715
JournalUgeskrift for Læger
Publication statusE-pub ahead of print - 20. May 2024


Dive into the research topics of 'Antiphospholipid antibodies and antiphospholipid syndrome'. Together they form a unique fingerprint.

Cite this